5th Edition Drug Pricing Transparency Congress
September 18-19, 2019 | USA
In light of recent focus on HHS’s proposal to eliminate rebates, the Senate Finance hearing with Pharma CEOs, and a strong legislative movement towards transparency, there is a heightened focus on drug pricing transparency in the United States. Recent federal and state rulings create lingering questions around legislation and compliance complexities that will impact the market in real-time causing uncertainty.